

Ref: FOI/GS/ID 8552

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

27 October 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to renal cell carcinoma and melanoma.

You asked:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- a. Avelumab + Axitinib*
- b. Axinitib*
- c. Cabozantinib*
- d. Everolimus*
- e. Lenvatinib + Everolimus*
- f. Nivolumab monotherapy*
- g. Nivolumab + Cabozantinib*
- h. Nivolumab + Ipilimumab*
- i. Pazopanib*
- j. Pembrolizumab monotherapy*
- k. Pembrolizumab + Axitinib*
- l. Pembrolizumab + Lenvatinib*
- m. Radiotherapy only*
- n. Sunitinib*
- o. Temsirolimus*
- p. Tivozanib*
- q. Other active systemic anti-cancer therapy*
- r. Palliative care only*

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

- a. Cobimetinib*
- b. Dabrafenib*
- c. Dabrafenib AND Trametinib*

- d. *Dacarbazine*
- e. *Denosumab*
- f. *Encorafenib AND Binimetinib*
- g. *Ipilimumab*
- h. *Ipilimumab AND Nivolumab*
- i. *Nivolumab*
- j. *Pembrolizumab*
- k. *Trametinib*
- l. *Vemurafenib*
- m. *Vemurafenib AND Cobimetinib*
- n. *Other active systemic anti-cancer therapy*
- o. *Palliative care only*

Q3. *Does you trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?*

Trust response:

1.

a	3
b	5
c	8
d	4
e	0
f	5
g	0
h	1
i	5
j	2
k	0
l	9
m	7
n	1
o	0
p	0
q	0
r	0

2.

a	0
b	0
c	25
d	0
e	1
f	10
g	0
h	9
i	11

j	54
k	0
l	1
m	0
n	1
o	0

3. We do not currently have any active trials for renal cell carcinoma.